Remove Cardiology Remove Clinical Development Remove Life Science
article thumbnail

Lilly’s Lepodisiran Achieves Over 90% Reduction in Heart Disease Marker in Phase II Trial

XTalks

The Phase II results were presented at the American College of Cardiology 2025 Scientific Sessions. Lilly shared that the ACCLAIM-Lp(a) Phase III clinical development program is currently enrolling. The findings suggest that lepodisiran could offer a durable treatment option for individuals with elevated Lp(a) levels.

Trials 59
article thumbnail

Bayer delivers on medical innovation fueling transformation of pharma business

The Pharma Data

We are taking bold steps into the future of drug development, investing strongly in areas at the forefront of the biomedical and technological revolution. Every year 47 million women enter menopause, a period where women are at the peak of their life’s activity, personally and professionally.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson’s Disease

The Pharma Data

“Patients with Parkinson’s disease are faced with life changing challenges and uncertainties that are not addressed by current treatments,” said Ahmed Enayetallah, M.D., Senior Vice President, Clinical Development, BlueRock Therapeutics. “We For more information, visit www.bluerocktx.com.

Trials 52
article thumbnail

BridgeBio’s Attruby (Acoramidis): A New, More Potent TTR Stabilizer for ATTR-CM

XTalks

Patient advocacy groups, including the Amyloidosis Support Groups led by Muriel Finkel, highlight the transformative impact of Attruby on the lives of those with ATTR-CM.

article thumbnail

Cardiac Biomarkers in Cardiovascular Clinical Trials: Caveats and Considerations

XTalks

This is a part of the precision cardiology approach and could lead to their use as prognostic indicators. Full-Service Clinical Development. The Double-Edged Sword of Cardiac Biomarkers.

article thumbnail

Bayer extends clinical development program for finerenone with Phase III study in patients with non-diabetic chronic kidney disease

The Pharma Data

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

article thumbnail

Bayer extends clinical development program for finerenone with Phase II study investigating the initial combination therapy with empagliflozin in patients with chronic kidney disease and type 2 diabetes

The Pharma Data

The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.